Replies to post #472281 on Zeev's Turnips Patch-No Politics (ZEEV)

[Zeev Hed]

I think it could retest sub $66, so I am waiting on AMGN.

[postman]

2MAR$--- from your earlier post on AMGN --- "Oral arguments of Rochs's request for a dismissal of AMGN's EPO patent infringement complaint are expected to begin on 5/10 at 2pm EST. The firm says its possible for the Judge to issue a decision at the hearing. If he rules in favor of Roche, the firm sees downside in AMGN shares limited to 1-2 points. If the Judge rules to proceed with the case or to pursue AMGN's request of discovery jurisdiction, the analyst believes shares could move up 5-10%. AMGN shares are Buy rated. For the latest breaking news, listen to Fly Radio " The daytrading action today probably won't reflect this upcoming event since it's still a couple of days away...

[butterfly111]

AMGN is up today due to this upgrade

"Amgen "outperform"

Monday, May 08, 2006 7:42:37 AM ET
Robert W. Baird

NEW YORK, May 8 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Amgen Inc (AMGN.NAS). The target price is set to $90.

In a research note published this morning, the analysts mention that a recent nephrologists survey indicated that the company’s Aranesp drug continues to gain share in the CKD market. Aranesp’s growth prospects are bright, with the surveyed nephrologists projecting an increase in the drug’s market share from 48.7% to 52.4% over the next six months, the analysts say. The drug is unlikely to face substantial competition from CERA, Robert W Baird adds."

http://www.newratings.com/analyst_news/article_1268834.html